CTOs on the Move

Kedrion

www.kedrion.com

 
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.kedrion.com
  • 400 Kelby St Fl 11
    Fort Lee, NJ USA 07024
  • Phone: 201.242.8900

Executives

Name Title Contact Details

Similar Companies

Cook Children's Medical Center - Cook Children's Community Clinics

Cook Children's Medical Center - Cook Children's Community Clinics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwest Missouri Office on Aging

Southwest Missouri Office on Aging is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axium Healthcare Pharmacy, Inc

Axium Healthcare Pharmacy, Inc. is a nationwide, privately-held Clinical Specialty Pharmacy licensed to operate in all 50 states. Axium Healthcare Pharmacy, Inc.

FHC Health Systems, Inc.

FHC Health Systems, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Histogenics

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics` regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics` first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.